This educational activity is supported by an independent educational grant from Pfizer. Pfizer was not involved in the development of content or selection of faculty for this educational activity.

Activity Description

This activity provides precise tactical tools that help clinicians prepare patients and care partners for ALK inhibitor therapy, recognise early or non-obvious treatment-related changes, and facilitate preference-informed communication in routine practice.

Target Audience

This Clinical Practice Support Toolkit has been designed to meet the educational needs of Multidisciplinary team members involved in ALK-positive NSCLC care.

Faculty

Kyle Concannon, MD

Dr. Concannon is Assistant Professor of Medical Oncology at the University of Colorado. His laboratory research focuses on overcoming treatment resistance in oncogene-driven lung cancers. Dr. Concannon collaborates with multidisciplinary teams to provide individualized care aimed at improving survival and quality of life. He also actively supports the cancer community as a co-host of the Cracking Cancer podcast.

Urs Weber, MD

Dr. Weber is an Assistant Professor of Thoracic Oncology at the Medical University of Colorado Anschutz Medical Campus. He earned his MD from the Yale University School of Medicine and holds board certifications in Internal Medicine and Medical Oncology. His clinical and research work focuses on thoracic oncology, with a specialization in cancer therapeutics and patient outcomes.

Disclosures

Disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education.

Kyle Concannon, MD, has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Consultant for AstraZeneca and Boehringer Ingelheim. Kyle Concannon, MD, does not intend to reference any unlabeled or unapproved uses of products during the presentation

Urs Weber, MD, has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Consultant for Boehringer Ingelheim, BlossomHill, EMD Serono and Johnson & Johnson. Urs Weber, MD, does not intend to reference any unlabeled or unapproved uses of products during the presentation

Staff

CCI staff, MedAll staff, and all planners and reviewers have no relevant financial relationships with ineligible companies to disclose.

Accreditation

This continuing education activity will be provided by Current Concepts Institute (CCI) and MedAll. Physicians, Nurse Practitioners, and Physician Assistants will be eligible for 0.25 AMA PRA Category 1 Credits™ Nurses for 0.25 ANCC Contact Hours. A statement of participation is available for other healthcare professionals.

Physicians

0.25 AMA PRA Category 1 Credits™ are available for this activity. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Current Concepts Institute and MedAll Education. Current Concepts Institute is accredited by the ACCME to provide continuing medical education for physicians.

Current Concepts Institute designates this online activity a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

Participation Costs

There is no cost to participate in this program.

Requirements for Completion

In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

Launch and Expiration Date: 14 September 2026 – 30 November 2027

Estimated time to complete this activity: 15 minutes

Unapproved and/or off-label use disclosure

Current Concepts Institute/MedAll requires CE faculty to disclose to the participants:

1. When products or procedures being discussed are off-label, unlabelled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Disclaimer

This activity is intended for educational purposes only and does not establish a standard of care or replace clinical judgment. Any therapeutic or diagnostic strategies discussed must be evaluated in the context of each patient’s clinical circumstances, risks, and current evidence.

Learners should consult authoritative clinical guidelines and approved product information when considering treatment decisions.
All materials are used with permission. The views expressed are those of the faculty and do not necessarily reflect those of the accredited providers, MedAll, or any supporters.

Content is accurate as of the date of release.